Bladder cancerPrognosisT cellA subset of bladder patients does not respond to BCG treatment effectively and the underlying reason behind this observation is currently unclear. CD4(+) T cells are composed of various subsets that each expresses a distinctive set of cytokines and can potently shift ...
Advanced Bladder Cancer For patients with advanced disease, platinum-basedcombination chemotherapyhas been the first-line treatment for decades, with cisplatin-based treatments yielding a better overall survival than carboplatin-based combinations (12-15 months vs. 9 months).62,63However most patients pr...
Tumor immune microenvironment dynamics and outcomes of prognosis in non-muscle-invasive bladder cancer.[Journal Article] Cancer Sci. 2024 Oct 11 [Online ahead of print]Kamitani R, Tanaka N, … Oya MCS Agents that target PD-1 and PD-L1 have been developed in the treatment of bladder cancer ...
Some practical points need to be considered when using BCG for bladder cancer treatment. BCG manufacturers recommend evaluating the tuberculosis status of the patient with a PPD (purified protein derivative) tuberculosis skin test before initiation of therapy, with some practitioners obtaining chest radiog...
Additionally, we aimed to anticipate the impact of these values on the diagnosis, prognosis, and treatment response of the disease. This study is the first to investigate the prognostic value of serum fibronectin and its genetic variations in the context of BCG treatment for NMIBC....
Objective: To review the outcome of all superficial transitional cell (TCC) bladder cancer treated with intravesical Bacille Calmette-Guerin (BCG) at one institution and, in particular, the prognosis for those patients who gained little benefit from BCG therapy.Patients and Methods: The notes of 12...
described the use of intravesical BCG treatment for superficial bladder cancer [11]. BCG activity, initially, is dependent on induction of inflammatory responses characterized by release of IL-1, IL-6, IL-8, TNF-α and GM-CSF [12], [13]. Subsequently, a variety of immune cells, including...
Successful treatment of disseminated BCG infection in a SCID patient with granulocyte colony stimulating factor Severe combined immunodeficiencies (SCID) are disorders with impairment of humoral and cellular immune functions. The prognosis of disseminated bacillus Ca... W Pariyaprasert,P Pacharn,N Visit...
BCG was first introduced into clinical use in urology in 1976 and remains the most effective form of intravesical treatment for non-muscle-invasive bladder cancer (NMIBC). Despite this successful history, BCG therapy is internationally underutilized and practice patterns of BCG administration vary ...
Bladder cancerPrognosisT cellA subset of bladder patients does not respond to BCG treatment effectively and the underlying reason behind this observation is currently unclear. CD4(+) T cells are composed of various subsets that each expresses a distinctive set of cytokines and can potently shift ...